The ADC targets CD79b on B cells; only CD79b-positive cells internalize the drug and release MMAE, which then binds the beta-tubulin (vinca) site to block microtubules and induce apoptosis. Tubulin expression alone does not confer susceptibility without CD79b-mediated uptake.